Fluorescence-guided development of a tricistronic vector encoding bimodal optical and nuclear genetic reporters for in vivo cellular imaging
- Adam Badar†1Email author,
- Louise Kiru†1, 2,
- Tammy L Kalber1,
- Amit Jathoul2,
- Karin Straathof2,
- Erik Årstad3,
- Mark F Lythgoe†1 and
- Martin Pule†2
© Badar et al.; licensee Springer. 2015
Received: 15 December 2014
Accepted: 10 March 2015
Published: 28 March 2015
In vivo imaging using genetic reporters is a central supporting tool in the development of cell and gene therapies affording us the ability to selectively track the therapeutic indefinitely. Previous studies have demonstrated the utility of the human norepinephrine transporter (hNET) as a positron emission tomography/single photon emission computed tomography (PET/SPECT) genetic reporter for in vivo cellular imaging. Here, our aim was to extend on this work and construct a tricistronic vector with dual optical (firefly luciferase) and nuclear (hNET) in vivo imaging and ex vivo histochemical capabilities. Guiding this development, we describe how a fluorescent substrate for hNET, 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP+), can be used to optimise vector design and serve as an in vitro functional screen.
Vectors were designed to co-express a bright red-shifted firefly luciferase (FLuc), hNET and a small marker gene RQR8. Genes were co-expressed using 2A peptide linkage, and vectors were transduced into a T cell line, SupT1. Two vectors were constructed with different gene orientations; FLuc.2A.RQR8.2A.hNET and hNET.2A.FLuc.2A.RQR8. hNET function was assessed using ASP+-guided flow cytometry. In vivo cellular conspicuity was confirmed using sequential bioluminescence imaging (BLI) and SPECT imaging of transduced SupT1 cells injected into the flanks of mice.
SupT1/FLuc.2A.RQR8.2A.hNET cells resulted in >4-fold higher ASP+ uptake compared to SupT1/hNET.2A.FLuc.2A.RQR8, suggesting that 2A orientation effected hNET function. SupT1/FLuc.2A.RQR8.2A.hNET cells were readily visualised with both BLI and SPECT, demonstrating high signal to noise at 24 h post 123I-meta-iodobenzylguanidine (MIBG) administration.
In this study, a pre-clinical tricistronic vector with flow cytometry, BLI, SPECT and histochemical capabilities was constructed, which can be widely applied in cell tracking studies supporting the development of cell therapies. The study further demonstrates that hNET function in engineered cells can be assessed using ASP+-guided flow cytometry in place of costly radiosubstrate methodologies. This fluorogenic approach is unique to the hNET PET/SPECT reporter and may prove valuable when screening large numbers of cell lines or vector/mutant constructs.
Cellular therapy with engineered cells is a promising area and is finding increasing application in regenerative medicine and cancer adoptive immunotherapy. In the clinical setting, T cell-based studies using chimeric antigen receptor (CAR) therapy have shown outstanding efficacy in refractory cancers [1-4]. More broadly, induced progenitor cells have been shown to regenerate different organs and systems in neurodegenerative , cardiovascular [6,7] and musculoskeletal  disorders. These therapeutics are different from standard therapies such as small molecules or proteins: they are essentially living therapies with no half-life, a complex engraftment and multifaceted in vivo behaviour.
A key limitation of pre-clinical and clinical development of advanced cellular therapies is lack of a satisfactory method for tracking these cells over sufficiently long periods of time. Direct or transient labelling methods, such as iron-labelled cells for magnetic resonance imaging (MRI) or 111In-oxine-labelled cells for single photon emission computed tomography (SPECT) are unsuitable for the time frame of immunotherapy studies. These allow imaging over hours/days [9-14], which are insufficient to study the complex biological integration and efficacy of cellular therapies, which can evolve over many weeks and months. A credible option is selective genetic modification of cells with a marker gene, using an integrating vector, to selectively track the cellular therapeutic indefinitely. Several different approaches to genetic reporter imaging have been proposed [15,16]. As a translational approach, positron emission tomography (PET) or SPECT show most promise. One such PET/SPECT genetic reporter is the human norepinephrine transporter (hNET) . In combination with radiolabelled noradrenaline analogues, meta-iodobenzylguanidine (MIBG) or meta-hydroxyephedrine (mHED), hNET engineered cells can be mapped in vivo via SPECT (123I-MIBG) or PET (124I-MIBG, 11C-mHED) [17-19]. It has been demonstrated that the technique has quantitative capabilities and has been used in longitudinal imaging studies of adoptively transferred T cells and gene therapy [20,21].
Here our aim was to construct a tricistronic vector co-expressing hNET with firefly luciferase (FLuc) and a compact suicide/marker gene, RQR8 . This triple construct extends upon the previously designed hNET-eGFP bicistronic construct . The hNET-FLuc construct is a novel addition for in vivo bioluminescence imaging (BLI), and the triple construct of hNET-FLuc-RQR8 has potential for histochemistry and therapeutic application. In this study, several vector constructs were designed and tested. Screening for a lead construct, we show that hNET function can be assessed in vitro using ASP+, a fluorescent analogue of the neurotoxin MPP+ and hNET substrate [23,24], in place of conventional and costly radiosubstrate methodologies. Using this approach, we determined the optimal gene orientation of the tricistronic construct. Finally, we performed sequential BLI and 123I-MIBG SPECT in vivo imaging.
Generation of tricistronic retroviral vectors and transduction of SupT1 cells
All cell culture medium and supplements were obtained from Lonza BioWhittaker (Walkersville, USA) unless otherwise stated. A human T cell lymphoblastic lymphoma-derived cell line (SupT1) was obtained from the American Type Culture Collection (ATCC, University Boulevard Manassas, USA) and cultured in RPMI 1640 media (St. Louis, USA) supplemented with 10% foetal bovine serum (FBS) and GlutaMAX (Gibco, Grand Island, USA). Cell lines were maintained at 37°C in a humidified 5% CO2 atmosphere. Three SupT1 cell populations were engineered, each with a different expression cassette; (1) an IRES-based bisictronic vector encoding for hNET and a cell surface marker CD34 (vector 1: SupT1/hNET.I.CD34), (2) a 2A peptide-linked tricistronic vector encoding for hNET, red-shifted codon optimised FLuc  and a highly compact marker/suicide gene RQR8  with 2A linkage at the N-terminus of hNET (vector 2: SupT1/FLuc.2A.RQR8.2A.hNET) and (3) at the C-terminus hNET (vector 3: SupT1/hNET.2A.FLuc.2A.RQR8). Moloney murine leukaemia virus (Mo-MuLV) long terminal repeat (LTR) promoter was used. SupT1 cells were transduced with RD114 pseudotyped supernatant generated from transfection of HEK-293T cells with the expression plasmids supplying Gagpol (gift from Elio Vanin, Baylor College of Medicine), RD114 envelope (gift from Mary Collins, University College London) PeqPam-env and each of the three hNET encoding vectors above. Transduction efficiency was determined by flow cytometry with αCD34-APC staining for vector 1 and QBEnd10 staining as previously described  for vectors 2 and 3.
Optimisation of staining conditions for ASP+-guided flow cytometry
SupT1 cells (1 × 106) transduced with hNET vector 1 were incubated at 37°C with varying concentrations of ASP+ (1 × 10−3, 5 × 10−3, 1 × 10−2, 5 × 10−2, 0.1, 0.5, 1 μM) for 10, 30, 60, 120 and 240 min. The cells were washed once with fluorescence activate cell sorting (FACS) buffer containing 1% FBS, phosphate saline buffer (PBS) and 50 mg/mL Normocin (InvivoGen, San Diego, USA). The supernatant was discarded and cells were re-suspended in 500 μL of FACS buffer. Flow cytometry was performed using Beckman Coulter Cyan instrument (Beckman Coulter, Brea, USA).
ASP+-guided flow sorting and functional assessment of hNET expressing SupT1 cells
Optimal ASP+ staining conditions determined above were used for ASP+-guided flow sorting of SupT1 cell lines expressing the three hNET vector constructs. Cells were prepared as described above. ASP+ mean fluorescence intensities (MFI) were determined pre- and post-FACS (Beckman Coulter MoFlo-XDP) using areas under the curve and subtracting any non-specific signal from non-transduced SupT1 (SupT1/NT) cell populations. Measurements were acquired in triplicates for each cell line and statistical significance of differences between mean values was obtained with IBM SPSS software using the one-way ANOVA and the Tukey’s HSD test.
In vitro radiotracer uptake assay
SupT1 cells expressing vectors 1 and 2 were further characterised by radiosubstrate uptake studies. 1 × 106 SupT1/hNET.I.CD34, SupT1/FLuc.2A.RQR8.2A.hNET and SupT1/NT cells were incubated for 30 min at 37°C with [125I]-MIBG (7.4 kBq). The cells were rapidly washed twice with 500 μL ice-cold PBS and the supernatant collected. Cell pellets were resuspended in 1 mL PBS. Radioactive uptake was determined by gamma counting (WIZARD, PerkinElmer, Beaconsfield, UK) of the resuspended cells and corresponding supernatants. Percentage [125I]-MIBG cell uptake was calculated by dividing the counts in the cell pellet by the total counts (counts in cell pellet + counts in supernatant). All experiments were performed in triplicates. The one-way ANOVA and the Tukey’s HSD test were used to determine the significance of differences between mean values.
In vivo bioluminescence and SPECT/CT imaging
All animal procedures were carried out in accordance with the UK Animals (Scientific Procedures) 1986 Act and institutional ethics regulation. SupT1/FLuc.2A.RQR8.2A.hNET cells (5 × 106) or non-transduced SupT1 cells (5 × 106) were injected into the subcutaneous space of the right flank of NOD/SCID mice (n = 3 in each group). Seven days later, BLI images (Biospace photon imager Optima system, Paris, France) were acquired 15 min post-intraperitoneal administration of 200 μL of D-Luciferin (10 mg/mL) using a 50 mm CCD lens with a sensitivity of 37 photons/s/sr/cm2. Images were analysed using Biospace M3 Vision software. 15 MBq (150 μL) of [123I]-MIBG (Mallinckrodt, Northampton, UK) was subsequently administered to animals via tail vein followed by whole body SPECT/CT imaging (nanoSPECT silver upgrade, Mediso, Budapest, Hungary) at 1 h, 4 h and 24 h post injection. Images were reconstructed using HiSPECT software (InviCRO, Boston, USA) followed by image processing and analysis using VivoQuant Software (InviCRO, Boston, USA).
ASP+-guided flow cytometry enables functional assessment of hNET engineered cells
Tricistronic pre-clinical vector for histochemistry, BLI and SPECT tracking of engineered cells
ASP+ screening to assess 2A peptide linkage orientation and hNET function
In vivo imaging of the tricistronic vector
With the development of new cellular and gene therapies, there is a need for non-invasive, readily available methods for detecting and quantifying the fate of these therapies in animal and man. As a translational approach, PET and SPECT genetic reporters have shown promise and have supported numerous clinical trials [27-29]. Various PET/SPECT reporter proteins have been proposed including the human sodium iodide symporter (hNIS), the hNET and the herpes simplex virus thymidine kinase (HSVtk) [16,17,30,31]. Difficulties in translating these into clinic include availability of clinically approved complementary radiotracers, early planning necessary to integrate the reporter protein and imaging protocol into trial design, incorporation of the reporter gene into the vector without exceeding the packaging capacity or affecting cell function and limited sensitivity in tissues with endogenous expression of the reporter protein.
In preclinical imaging, taking advantage of the strengths each modality (e.g. MRI, optical and nuclear) has to offer, the use of multimodal multicistronic reporters is becoming increasingly popular . For example, co-expression of PET and BLI reporters would enable rapid, affordable and sensitive BLI, alongside complementary tomographic and quantitative PET capabilities. Expression vectors are often composed of multiple genes (e.g. a therapeutic, a marker gene, a suicide gene and a reporter gene) some of which can be large surface proteins, which may tax the vector packaging capacity and transcriptional efficiency. Strategies which promote maximising vector space are therefore essential and may include gene and protein truncation [22,32], efficient gene coupling approaches [33,34] and the utility of dual purpose genes [22,35,36].
Here, we have developed a trisictronic expression vector containing a nuclear reporter (hNET), a BLI reporter (FLuc) and a highly compact dual-purpose marker/suicide gene (RQR8). To achieve a compact vector, genes were linked with the ‘self-cleaving’ small 2A peptide, driving obligate co-expression under a single promoter (26). Exploiting the endogenous fluorescent properties of the hNET substrate ASP+, it was possible to simultaneously, and efficiently, sort pure cell populations and evaluate reporter function. Such a system is unique to hNET as a nuclear reporter and may circumvent the need for in vitro radioligand cell uptake assays prior to in vivo use. Furthermore, as hNET positive cells can be efficiently sorted using ASP+-guided flow cytometry, hNET could double up as a marker gene, leaving more flexibility to insert other genes in the expression vector.
Using ASP+-guided flow cytometry, we demonstrated that residual 2A amino acids attached to the C-terminus of the transcribed hNET markedly reduced the protein capacity to accumulate substrate into the cell. This finding further corroborates previous structure/function studies indicating the critical contribution of the hNET C-terminus to transporter trafficking, stability and function [37,38]. Consequently, an expression vector with 2A cleavage site upstream of hNET was taken forward for in vivo assessment. FLuc/hNET cells were successfully visualised using sequential BLI and SPECT imaging demonstrating high target to background tumour visualisation at 24 h post 123I-MIBG administration.
In conclusion, exploiting the unique fluorescent properties of ASP+, we have been able to explore hNET function in engineered cells. We have constructed a novel pre-clinical tricistronic vector with BLI, SPECT, flow cytometry and histochemical capabilities, which can be widely applied in cell tracking studies supporting the development of cell therapies. Further investigation with regard to quantitatively correlating ASP+ and MIBG kinetics in hNET engineered cells, as well as determining the in vivo sensitivity of the technique is required and should be performed for each new cell line under investigation.
This work was financially supported by the following: The Comprehensive Cancer Imaging Centre at KCL & UCL jointly funded by Cancer Research UK (CRUK) and the Engineering and Physical Sciences Research Council (EPSRC), the UK Regenerative Medicine Platform (UKRMP MR/K026739/1) Safety Hub MRC, EPSRC and BBSRC, and EPSRC Early Career Fellowship (EP/L006472/1) Generation of Multi-Modal Imaging Mesenchymal Stem Cells.
- Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14(11):1264–70.View ArticlePubMed CentralPubMedGoogle Scholar
- Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725–33.View ArticlePubMed CentralPubMedGoogle Scholar
- Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119:2709–20.View ArticlePubMed CentralPubMedGoogle Scholar
- Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5:177ra38.PubMed CentralPubMedGoogle Scholar
- Lindvall O, Kokaia Z. Stem cells in human neurodegenerative disorders–time for clinical translation? J Clin Invest. 2010;120(1):29–40.View ArticlePubMed CentralPubMedGoogle Scholar
- Miyahara Y, Nagaya N, Kataoka M, Yanagawa B, Tanaka K, Hao H, et al. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat Med. 2006;12(4):459–65.View ArticlePubMedGoogle Scholar
- Yoshioka T, Ageyama N, Shibata H, Yasu T, Misawa Y, Takeuchi K, et al. Repair of infarcted myocardium mediated by transplanted bone marrow-derived CD34 + stem cells in a nonhuman primate model. Stem Cells. 2005;23(3):355–64.View ArticlePubMedGoogle Scholar
- Bruder SP, Fink DJ, Caplan AI. Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J Cell Biochem. 1994;56(3):283–94.View ArticlePubMedGoogle Scholar
- Balaban EP, Simon TR, Frenkel EP. Toxicity of indium-111 on the radiolabeled lymphocyte. J Nucl Med. 1987;28(2):229–33.PubMedGoogle Scholar
- Brenner W, Aicher A, Eckey T, Massoudi S, Zuhayra M, Koehl U, et al. 111In-labeled CD34+ hematopoietic progenitor cells in a rat myocardial infarction model. J Nucl Med. 2004;45(3):512–8.PubMedGoogle Scholar
- Nowak B, Weber C, Schober A, Zeiffer U, Liehn EA, von Hundelshausen P, et al. Indium-111 oxine labelling affects the cellular integrity of haematopoietic progenitor cells. Eur J Nucl Med Mol Imaging. 2007;34(5):715–21.View ArticlePubMedGoogle Scholar
- Botti C, Negri DR, Seregni E, Ramakrishna V, Arienti F, Maffioli L, et al. Comparison of three different methods for radiolabelling humanactivated T lymphocytes. Eur J Nucl Med Mol Imaging. 1997;24:497–504.Google Scholar
- Carr HM, Smyth JV, Rooney OB, Dodd PD, Sharma H, Walker MG. Limitations of in-vitro labeling of endothelial cells with indium-111 oxine. Cell Transplant. 1995;4(3):291–6.View ArticlePubMedGoogle Scholar
- Li Z, Suzuki Y, Huang M, Cao F, Xie X, Connolly AJ, et al. Comparison of reporter gene and iron particle labeling for tracking fate of human embryonic stem cells and differentiated endothelial cells in living subjects. Stem Cells. 2008;26:864–7.View ArticlePubMed CentralPubMedGoogle Scholar
- Kang JH, Chung JK. Molecular-genetic imaging based on reporter gene expression. J Nucl Med. 2008;49(2):164S–79.View ArticlePubMedGoogle Scholar
- Gambhir SS, Yaghoubi SS, Campbell RE, Davidson MW, Doyle TC, Wang Q et al. Molecular imaging with reporter genes. Cambridge University Press. 2010. ISBN: 9780521882330.Google Scholar
- Anton M, Wagner B, Haubner R, Bodenstein C, Essien BE, Bönisch H, et al. Use of the norepinephrine transporter as a reporter gene for non-invasive imaging of genetically modified cells. J Gene Med. 2004;6(1):119–26.View ArticlePubMedGoogle Scholar
- Moroz MA, Serganova I, Zanzonico P, Ageyeva L, Beresten T, Dyomina E, et al. Imaging hNET reporter gene expression with 124I-MIBG. J Nucl Med. 2007;48(5):827–36.View ArticlePubMedGoogle Scholar
- Buursma AR, Beerens AM, de Vries EF, van Waarde A, Rots MG, Hospers GA, et al. The human norepinephrine transporter in combination with 11C-m-hydroxyephedrine as a reporter gene/reporter probe for PET of gene therapy. J Nucl Med. 2005;46(12):2068–75.PubMedGoogle Scholar
- Brader P, Kelly KJ, Chen N, Yu YA, Zhang Q, Zanzonico P, et al. Imaging a genetically engineered oncolytic vaccinia virus (GLV-1h99) using a human norepinephrine transporter reporter gene. Clin Cancer Res. 2009;15(11):3791–801.View ArticlePubMedGoogle Scholar
- Doubrovin MM, Doubrovina ES, Zanzonico P, Sadelain M, Larson SM, O’Reilly RJ. In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene. Cancer Res. 2007;67(24):11959–69.View ArticlePubMedGoogle Scholar
- Philip B, Kokalaki E, Mekkaoui L, Thomas S, Straathof K, Flutter B, et al. A highly compact epitope-based marker / suicide gene for easier and safer T-cell therapy. Blood. 2014;124(8):1277–87.View ArticlePubMedGoogle Scholar
- Bönisch H, Brüss M. The norepinephrine transporter in physiology and disease. Handb Exp Pharmacol. 2006;175:485–524.View ArticlePubMedGoogle Scholar
- Mason JN, Farmer H, Tomlinson ID, Schwartz JW, Savchenko V, DeFelice LJ, et al. Novel fluorescence-based approaches for the study of biogenic amine transporter localization, activity, and regulation. J Neurosci Methods. 2005;143(1):3–25.View ArticlePubMedGoogle Scholar
- Branchini BR, Ablamsky DM, Davis AL, Southworth TL, Butler B, Fan F, et al. Red-emitting luciferases for bioluminescence reporter and imaging applications. Anal Biochem. 2010;396(2):290–7.View ArticlePubMedGoogle Scholar
- Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF, et al. Correction of multi-gene deficiency in vivo using a single ‘self-cleaving’ 2A peptide-based retroviral vector. Nat Biotechnol. 2004;22(5):589–94.View ArticlePubMedGoogle Scholar
- Peñuelas I, Mazzolini G, Boán JF, Sangro B, Martí-Climent J, Ruiz M, et al. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology. 2005;128(7):1787–95.View ArticlePubMedGoogle Scholar
- Jacobs A, Voges J, Reszka R, Lercher M, Gossmann A, Kracht L, et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet. 2001;358(9283):727–9.View ArticlePubMedGoogle Scholar
- Yaghoubi S, Jensen MC, Satyamurthy N, Budhiraja S, Paik D, Czernin J, et al. Non-invasive detection of therapeutic cytolytic T cells with [18F]FHBG positron emission tomography in a glioma patient. Nat Clin Pract Oncol. 2008;6(1):53–8.View ArticlePubMed CentralPubMedGoogle Scholar
- Shin JH, Chung JK, Kang JH, Lee YJ, Kim KI, Kim CW, et al. Feasibility of sodium/iodide symporter (NIS) gene as a new imaging reporter gene: comparison with HSV1-tk. Eur J Nucl Med Mol Imaging. 2004;31:425–32.View ArticlePubMedGoogle Scholar
- Gambhir SS, Barrio JR, Wu L, Iyer M, Namavari M, Satyamurthy N, et al. Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir. J Nucl Med. 1998;39:2003–11.PubMedGoogle Scholar
- Wang B, Li J, Fu FH, Chen C, Zhu X, Zhou L, et al. Construction and analysis of compact muscle-specific promoters for AAV vectors. Gene Ther. 2008;15(22):1489–99.View ArticlePubMedGoogle Scholar
- Chan HY VS, Xing X, Kraus P, Yap SP, Ng P, et al. Comparison of IRES and F2A-based locus-specific multicistronic expression in stable mouse lines. PLoS One. 2011;6(12):e28885.View ArticlePubMed CentralPubMedGoogle Scholar
- Kim JH, Lee SR, Li LH, Park HJ, Park JH, Lee KY, et al. High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS One. 2011;6(4):e18556.View ArticlePubMed CentralPubMedGoogle Scholar
- Qin C, Cheng K, Chen K, Hu X, Liu Y, Lan X, et al. Tyrosinase as a multifunctional reporter gene for photoacoustic/MRI/PET triple modality molecular imaging. Sci Rep. 2013;3:1490.View ArticlePubMed CentralPubMedGoogle Scholar
- Patrick PS, Hammersley J, Loizou L, Kettunen MI, Rodrigues TB, Hu DE, et al. Dual-modality gene reporter for in vivo imaging. Proc Natl Acad Sci. 2013;111(1):415–20.View ArticlePubMed CentralPubMedGoogle Scholar
- Distelmaier F, Wiedemann P, Brüss M, Bönisch H. Functional importance of the C-terminus of the human norepinephrine transporter. J Neurochem. 2004;91(3):537–46.View ArticlePubMedGoogle Scholar
- Sogawa C, Kumagai K, Sogawa N, Morita K, Dohi T, Kitayama S. C-terminal region regulates the functional expression of human noradrenaline transporter splice variants. Biochem J. 2007;401(1):185–95.View ArticlePubMed CentralPubMedGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.